Cargando…
The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19
Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID/PASC. The alveolar tissue and adjacent capil...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592739/ https://www.ncbi.nlm.nih.gov/pubmed/36304538 http://dx.doi.org/10.3389/fcvm.2022.1007636 |
_version_ | 1784814995918290944 |
---|---|
author | Jaeger, Beate Roxane Arron, Hayley Emma Kalka-Moll, Wiltrud M. Seidel, Dietrich |
author_facet | Jaeger, Beate Roxane Arron, Hayley Emma Kalka-Moll, Wiltrud M. Seidel, Dietrich |
author_sort | Jaeger, Beate Roxane |
collection | PubMed |
description | Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID/PASC. The alveolar tissue and adjacent capillaries show inflammatory and procoagulatory activation with cell necrosis, thrombi, and massive fibrinoid deposits, namely, unsolvable microthrombi, which results in an obstructed gas exchange. Heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.) apheresis solves these problems by helping the entire macro- and microcirculation extracorporeally. It uses unfractionated heparin, which binds the spike protein and thereby should remove the virus (debris). It dissolves the forming microthrombi without bleeding risk. It removes large amounts of fibrinogen (coagulation protein), which immediately improves the oxygen supply in the capillaries. In addition, it removes the precursors of both the procoagulatory and the fibrinolytic cascade, thus de-escalating the entire hemostaseological system. It increases myocardial, cerebral, and pulmonary blood flow rates, and coronary flow reserve, facilitating oxygen exchange in the capillaries, without bleeding risks. Another factor in COVID is the “cytokine storm” harming microcirculation in the lungs and other organs. Intervention by H.E.L.P. apheresis could prevent uncontrollable coagulation and inflammatory activity by removing cytokines such as interleukin (IL)-6, IL-8, and TNF-α, and reduces C-reactive protein, and eliminating endo- and ecto-toxins, without touching protective IgM/IgG antibodies, leukocyte, or platelet function. The therapy can be used safely in combination with antiviral drugs, antibiotics, anticoagulants, or antihypertensive drugs. Long-term clinical experience with H.E.L.P. apheresis shows it cannot inflict harm upon patients with COVID-19. |
format | Online Article Text |
id | pubmed-9592739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95927392022-10-26 The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 Jaeger, Beate Roxane Arron, Hayley Emma Kalka-Moll, Wiltrud M. Seidel, Dietrich Front Cardiovasc Med Cardiovascular Medicine Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID/PASC. The alveolar tissue and adjacent capillaries show inflammatory and procoagulatory activation with cell necrosis, thrombi, and massive fibrinoid deposits, namely, unsolvable microthrombi, which results in an obstructed gas exchange. Heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.) apheresis solves these problems by helping the entire macro- and microcirculation extracorporeally. It uses unfractionated heparin, which binds the spike protein and thereby should remove the virus (debris). It dissolves the forming microthrombi without bleeding risk. It removes large amounts of fibrinogen (coagulation protein), which immediately improves the oxygen supply in the capillaries. In addition, it removes the precursors of both the procoagulatory and the fibrinolytic cascade, thus de-escalating the entire hemostaseological system. It increases myocardial, cerebral, and pulmonary blood flow rates, and coronary flow reserve, facilitating oxygen exchange in the capillaries, without bleeding risks. Another factor in COVID is the “cytokine storm” harming microcirculation in the lungs and other organs. Intervention by H.E.L.P. apheresis could prevent uncontrollable coagulation and inflammatory activity by removing cytokines such as interleukin (IL)-6, IL-8, and TNF-α, and reduces C-reactive protein, and eliminating endo- and ecto-toxins, without touching protective IgM/IgG antibodies, leukocyte, or platelet function. The therapy can be used safely in combination with antiviral drugs, antibiotics, anticoagulants, or antihypertensive drugs. Long-term clinical experience with H.E.L.P. apheresis shows it cannot inflict harm upon patients with COVID-19. Frontiers Media S.A. 2022-10-11 /pmc/articles/PMC9592739/ /pubmed/36304538 http://dx.doi.org/10.3389/fcvm.2022.1007636 Text en Copyright © 2022 Jaeger, Arron, Kalka-Moll and Seidel. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Jaeger, Beate Roxane Arron, Hayley Emma Kalka-Moll, Wiltrud M. Seidel, Dietrich The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 |
title | The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 |
title_full | The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 |
title_fullStr | The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 |
title_full_unstemmed | The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 |
title_short | The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 |
title_sort | potential of heparin-induced extracorporeal ldl/fibrinogen precipitation (h.e.l.p.)-apheresis for patients with severe acute or chronic covid-19 |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592739/ https://www.ncbi.nlm.nih.gov/pubmed/36304538 http://dx.doi.org/10.3389/fcvm.2022.1007636 |
work_keys_str_mv | AT jaegerbeateroxane thepotentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19 AT arronhayleyemma thepotentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19 AT kalkamollwiltrudm thepotentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19 AT seideldietrich thepotentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19 AT jaegerbeateroxane potentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19 AT arronhayleyemma potentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19 AT kalkamollwiltrudm potentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19 AT seideldietrich potentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19 |